Repligen (NASDAQ:RGEN) COO Sells $331,301.11 in Stock

Repligen Corporation (NASDAQ:RGEN) COO James Bylund sold 2,191 shares of the stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the transaction, the chief operating officer directly owned 21,520 shares of the company’s stock, valued at $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

James Bylund also recently made the following trade(s):

• On Tuesday, November 18th, James Bylund sold 2,191 shares of Repligen stock. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11.

Repligen Stock Performance

Repligen stock traded up $2.02 during mid-day trading on Wednesday, reaching $155.08. 693,747 shares of the company traded hands, compared to its average volume of 824,500. The firm’s fifty day moving average is $142.29 and its two-hundred day moving average is $129.81. The company has a market capitalization of $8.73 billion, a price-to-earnings ratio of 7,757.88, a price-to-earnings-growth ratio of 3.32 and a beta of 1.15. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The firm had revenue of $188.81 million for the quarter, compared to analyst estimates of $181.23 million. During the same period in the previous year, the company earned $0.43 earnings per share. The business’s quarterly revenue was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, equities research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its holdings in Repligen by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock worth $962,711,000 after buying an additional 430,039 shares in the last quarter. United Capital Financial Advisors LLC acquired a new position in shares of Repligen in the third quarter worth about $368,387,000. Holocene Advisors LP raised its position in shares of Repligen by 47.0% in the third quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock worth $184,077,000 after acquiring an additional 440,290 shares during the period. Alliancebernstein L.P. boosted its stake in shares of Repligen by 21.8% during the 3rd quarter. Alliancebernstein L.P. now owns 1,104,171 shares of the biotechnology company’s stock worth $147,595,000 after acquiring an additional 197,778 shares in the last quarter. Finally, Brown Capital Management LLC grew its position in shares of Repligen by 16.3% during the 2nd quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock valued at $125,036,000 after acquiring an additional 141,241 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Barclays raised their price objective on Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Wells Fargo & Company reduced their price target on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, July 30th. HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. HSBC began coverage on shares of Repligen in a report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price objective on the stock. Finally, Stephens upgraded shares of Repligen to an “overweight” rating and set a $160.00 price objective on the stock in a research note on Tuesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $173.85.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.